MSweb forum

Australian research unlocks [URL="http://www.msra.org.au/unlocks-genetic-mechanism"][U]genetic mechanism behind vitamin D and its role in MS[/U][/URL]

[QUOTE]New research published in the Journal of Genes & Immunity has identified the genetic switch which shows how immune cells are controlled by vitamin D and sheds light on how vitamin D may be used as a therapy for MS.

The research group, led by Professor David Booth at the Westmead Institute for Medical Research, says it has long been known that vitamin D deficiency is associated with autoimmune diseases such as multiple sclerosis (MS), but until now researchers did not know the exact biological mechanism for this association.

'Understanding the genes that control the vitamin D response in MS and the types of immune cells that offer protection, helps us to pave the way for more targeted approaches for people with this disease,' Professor David Booth said.[/QUOTE]
[QUOTE]Professor Booth and his team discovered that three known MS risk genes, which control vitamin D activation, are “turned on” in specific cells called myeloid cells. Myeloid cells are a type of immune cell found in the skin and lymph nodes. Until now, nobody has looked at how the genes work in these cells in relation to MS and vitamin D.

With the help of a powerful technique called ChIP Seq, which analyses protein interactions with DNA, they found that the genes, including the risk genes, are controlled by vitamin D in the myeloid cells.

'We now have the key to help develop more targeted treatments to help people with this devastating disease,' Professor Booth said.[/QUOTE]

PubMed

Link naar publicatie in PubMed
[url]http://www.ncbi.nlm.nih.gov/pubmed/26986782[/url]

Mooi artikel over zonlicht.

Sunlight: For Better or For Worse? A Review of Positive and Negative Effects of Sun Exposure
Han van der Rhee1, Esther de Vries2, Claudia Coomans3, Piet van de Velde4, Jan Willem Coebergh5
Cancer Research Frontiers. 2016 May; 2(2): 156-183.
doi: 10.17980/2016.156

[url]http://cancer-research-frontiers.org/wp ... -2-156.pdf[/url]

.

High-dose vitamin D may boost diversity of the gut microbiome: Study

High-dose vitamin D may [URL="http://www.nutraingredients-usa.com/Res ... iome-Study"][U]boost diversity of the gut microbiome[/U][/URL]: Study

[QUOTE]Vitamin D3 may increase bacterial richness in the upper gastrointestinal tract and reduce opportunistic pathogens, says a new study from Austria.[/QUOTE]

Weer een interessante over vitamine D: het helpt niet alleen in het voorkomen van MS, maar helpt ook bij de aanmaak van nieuwe myeline.

[url=http://www.ms-uk.org/july9]Vitamin D ‘could repair nerve damage’[/url]

Voor het volledige artikel
[url=http://jcb.rupress.org/content/211/5/975.full.pdf+html]artikel[/url]

groetjes, Marc

Magnesium, vitamin D status and mortality

[URL="http://www.ncbi.nlm.nih.gov/pmc/article ... 11-187.pdf"][U]Magnesium, vitamin D status and mortality[/U][/URL]:
results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III

[QUOTE][B]Abstract[/B]

[B]Background[/B]: Magnesium plays an essential role in the synthesis and metabolism of vitamin D and magnesium supplementation substantially reversed the resistance to vitamin D treatment in patients with magnesiumdependent vitamin-D-resistant rickets. We hypothesized that dietary magnesium alone, particularly its interaction with vitamin D intake, contributes to serum 25-hydroxyvitamin D (25(OH)D) levels, and the associations between serum 25(OH)D and risk of mortality may be modified by magnesium intake level.

[B]Methods[/B]: We tested these novel hypotheses utilizing data from the National Health and Nutrition Examination Survey (NHANES) 2001 to 2006, a population-based cross-sectional study, and the NHANES III cohort, a populationbased cohort study. Serum 25(OH)D was used to define vitamin D status. Mortality outcomes in the NHANES III cohort were determined by using probabilistic linkage with the National Death Index (NDI).

[B]Results[/B]: High intake of total, dietary or supplemental magnesium was independently associated with significantly reduced risks of vitamin D deficiency and insufficiency respectively. Intake of magnesium significantly interacted with intake of vitamin D in relation to risk of both vitamin D deficiency and insufficiency. Additionally, the inverse association between total magnesium intake and vitamin D insufficiency primarily appeared among populations at high risk of vitamin D insufficiency. Furthermore, the associations of serum 25(OH)D with mortality, particularly due to cardiovascular disease (CVD) and colorectal cancer, were modified by magnesium intake, and the inverse associations were primarily present among those with magnesium intake above the median.

[B]Conclusions[/B]: Our preliminary findings indicate it is possible that magnesium intake alone or its interaction with vitamin D intake may contribute to vitamin D status. The associations between serum 25(OH)D and risk of mortality may be modified by the intake level of magnesium. Future studies, including cohort studies and clinical trials, are necessary to confirm the findings.[/QUOTE]

Sotirchos ES, Bhargava P, Eckstein C, Van Haren K, Baynes M, Ntranos A, Gocke A, Steinman L, Mowry EM, Calabresi PA.
[URL="http://www.ncbi.nlm.nih.gov/pubmed/26718578"]Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.[/URL]
Neurology. 2016 Jan 26;86(4):382-90.

[QUOTE]Abstract
OBJECTIVE:
To study the safety profile and characterize the immunologic effects of high- vs low-dose cholecalciferol supplementation in patients with multiple sclerosis (MS).
METHODS:
In this double-blind, single-center randomized pilot study, 40 patients with relapsing-remitting MS were randomized to receive 10,400 IU or 800 IU cholecalciferol daily for 6 months. Assessments were performed at baseline and 3 and 6 months.
RESULTS:
Mean increase of 25-hydroxyvitamin D levels from baseline to final visit was larger in the high-dose group (34.9 ng/mL; 95% confidence interval [CI] 25.0-44.7 ng/mL) than in the low-dose group (6.9 ng/mL; 95% CI 1.0-13.7 ng/mL). Adverse events were minor and did not differ between the 2 groups. Two relapses occurred, one in each treatment arm. In the high-dose group, we found a reduction in the proportion of interleukin-17(+)CD4(+) T cells (p = 0.016), CD161(+)CD4(+) T cells (p = 0.03), and effector memory CD4(+) T cells (p = 0.021) with a concomitant increase in the proportion of central memory CD4(+) T cells (p = 0.018) and naive CD4(+) T cells (p = 0.04). These effects were not observed in the low-dose group.
CONCLUSIONS:
Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells.
CLASSIFICATION OF EVIDENCE:
This study provides Class I evidence that cholecalciferol supplementation with 10,400 IU daily is safe and well-tolerated in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects.[/QUOTE]

Goed onderzoek naar de voordelen van vitamine D3 10.400 IU/dag bij MS. 10.400 IU/dag wordt goed verdragen. 3 proefpersonen werden er wel misselijk van, maar waarschijnlijk komt dat omdat ze geen Magnesium slikten, maar dat zal ik nog even vragen.

.

Progressie van MS en Vitamine D

[URL="http://www.msweb.nl/klinisch/4795"][U]Van MS-web[/U][/URL]: Progressie van MS en Vitamine D

[QUOTE]De progressie van MS en de functie beperkingen bij MS blijken niet gerelateerd te zijn aan de Vitamine D status in het bloed. Dit blijkt uit een 3 jaar follow up studie.

Deze studie keek naar de relatie tussen de belangrijkste functionele beperkingen die ontstaan bij MS en de Vitamine D waardes. De studie geeft wel aan dat er een significant verband is tussen de relapses en vitamine D status bij jongeren met MS (≤ 37,5 jaar).

De studie is opgezet als vervolg van de studies die aangetoond hebben dat zowel het ontstaan van MS als de ziekte activiteit van MS kan worden gerelateerd met de vitamine D status in het bloed.

In totaal hebben er 554 mensen met MS mee gedaan in het onderzoek. De hoeveelheid vitamine D in het lichaam van de mensen met MS werd gemeten tijdens de routine klinische onderzoeken. Daarna werd er statistisch gekeken naar de Vitamine D waardes in het bloed en hoe die veranderende ten opzichte van de ziekte progressie, relapses en functionele beperkingen.

Vervolg studies zullen kijken of een hoge dosis aan Vitamine D, de progressie van MS en progressie van functiebeperkingen kan verminderen. Ook hier zal weer gebruik gemaakt worden van een follow up studie over langer termijn.[/QUOTE]

Bij dit onderzoek kregen de deelnemers geen vitamine D suppletie. Uit anders onderzoek blijkt dat mensen met MS over het algemeen een lager vitamine D gehalte hebben dan mensen zonder MS.

Het verbaast mij dan ook niets dat vitamine D in zo'n geval er niet veel toe doet.

.

Alleen de laatste alinea is interessant, de rest is....tsja, zonde van tijd en geld?